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Abstract Although Fingolimod is registered as a second-
line drug in relapsing-remittend multiple sclerosis (RRMS)
in Europe there are no clinical studies available comparing
Fingolimod (FTY) and Natalizumab (N). This observa-
tional cohort-study used health data routinely collected in
outpatient neurology practices throughout Germany com-
pleting a treatment period of 12 months included 237
patients starting on N and 190 patients on FTY because of
failure of the first-line treatment. Mean relapse rate dras-
tically decreased in both treatment groups within three -
months of therapy in a similar degree and remained on a
low level. Both treatment groups saw a similar proportion
of patients with unchanged and improved EDSS (80.53 %
in FTY, 79.32 % in N). There was no statistically signifi-
cant difference between the proportion of patients being
relapse free (75.79 % in FTY, 71.73 % in N), progression
free (87.39 % in FTY, 82.70 % in N) or relapse and pro-
gression free (71.05 % in FTY, 62.03 % in N) at
12 months in both strata. Clinical efficacy of FTY and N in
RRMS second-line-therapy was similar during the first
12 months of treatment.
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Introduction
Clinical studies of the efficacy of Fingolimod (FTY)
investigated FTY as first line medication in relapsing-
remitted multiple sclerosis (RRMS) in comparison to pla-
cebo [1] or once weekly intramuscular interferon-b-1a [2]
showing its superiority regarding relapse rate, progression
of disability and end points of MRI. While the United
States Food and Drug Administration (FDA) and other
countries registered FTY as first-line therapy in RRMS,
FTY was registered in Europe by the European Medicines
Agency (EMA) only as a second line therapy in RRMS. So
far the only registered second line medication in RRMS in
Europe had been Natalizumab (N). Clinical trials with N
showed its superiority in comparison with placebo [3] and
with ongoing interferon therapy alone [4]. This is the first
study comparing clinical efficacy of FTY as a second line
drug in RRMS with N in a real-life cohort.
Methods
This is an observational cohort-study using health data rou-
tinely collected in outpatient neurology practices throughout
Germany who are members of the NeuroTransConcept net-
work. Sex, age, relapses, EDSS and medication are docu-
mented digitally in-time during clinical visits at least once
within 3-month periods in all patients with MS in the partic-
ipating practices. All neurologists are trained to document
these data in a standardized way in the digital data source and
are certified EDSS-raters. This data acquisition protocol is
approved by the ethical committee of the Bavarian Medical
Board (Bayerische Landesa¨rztekammer, 14.06.2012).
The data of the participating neurology practices are
pooled anonymously to form the database of the study.
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This cohort analysis includes all RRMS patients starting on
either FTY or N in the two years between 1 February 2009
and 31 January 2011 and who completed at least
12 months of treatment by 31 January 2012. The decision
to change from first-line to second line therapy and the
choice of treatment were at the discretion of the treating
neurologist and the patient in accordance with the label of
the two second-line therapy drugs in Germany.
The primary outcome parameters were progression, as
measured by worsening in the EDSS and relapse rate during
the first 12 months of treatment with either N or FTY. Dif-
ferences between treatment groups for demographic param-
eters, EDSS, relapse rate were tested with a t test. Kaplan–
Meyer survival curves were calculated analyzing the propor-
tion of patients without progression of EDSS, new relapses as
well as for the composite parameter freedom of clinical dis-
ease activity, combining lack of relapse and progression.
Progression of EDSS was defined as an increase of the EDSS
score by one point, if baseline EDSS was smaller than 5.5, or
0.5 points if baseline EDSS was equal or higher than 5.5.
Population
Two hundred and thirty-seven patients starting on N and
190 patients on FTY were identified and included. Their
demographic characteristics are shown in Table 1.
Patients with FTY had a significantly lower EDSS at
baseline and less relapses during the three months prior to
treatment than N, while the annualized relapse rate did not
differ significantly between groups.
Results
Mean EDSS scores in both treatment groups showed a
slight tendency to improve, without statistically significant
change over time within groups or difference of change
between groups (Fig. 1).
Mean relapse rate decreased drastically in both treat-
ment groups within three months of therapy in a similar
degree and remained on a low level over the documented
observation time (Fig. 1).
Both treatment groups saw a similar proportion of
patients with unchanged and improved EDSS (80.53 % in
FTY, 79.32 % in N) and deteriorated EDSS. The higher
proportion of patients free of clinical disease activity in
FTY was not statistically significant compared to N
(Fig. 2).
Both treatments achieved a similar proportion of
patients being relapse free (v2 p value 0.35), progression
free (Chi square p value 0.18) or relapse and progression
free (v2 p value 0.05) at 12 months (Fig. 3).
To address potential effects of different baseline
demographics of both cohorts, adjusted linear regression
analyses have been performed. All clinical and demo-
graphic baseline parameters revealed low and non-signifi-
cant correlation coefficients for the outcome parameter
EDSS progression (proportion of patients without pro-
gression). Regarding the outcome parameter relapse
activity between months 9 and 12, age, EDSS at baseline
and number of relapses at baseline revealed weak but
significant correlations (see Table 2). These weak corre-
lations account for 3.2 % of the variance at most.
To balance observed covariates between subjects from
this observational study we employed the propensity score
method in addition. In brief, ‘‘propensity score stratifica-
tion’’ was performed according to the method published by
Rosenbaum and Rubin [5]. The same baseline character-
istics (age, sex, treatment group, relapses at baseline, EDSS
score at baseline), as considered in the adjusted regression
model, were also considered in the propensity score strat-
ification method. For each covariate one could see the
reduction in imbalance produced by the propensity score.
There appeared to be no indication of significant residual
imbalance.
The results of the propensity score regression analysis
(see Table 3) are fully in line with the adjusted linear
regression model already presented in the paper. No sig-
nificant effect of baseline differences on clinical parame-
ters, like relapses and progression, was found. This is not
surprising as this fact has already been stated by Senn et al.
[6].
Discussion
Both primary outcome parameters EDSS and quarterly
relapse rate stabilized and improved, respectively, within
three months after initiating treatment with FTY or N to a
Table 1 Demographic data of patient groups
Parameter Natalizumab Fingolimod p value
Number of patients fully
documented
237 190




Mean duration of MS
(years)
9.15 ± 6.9 9.89 ± 6.9 0.3577
Mean EDSS at baseline 3.3 ± 1.8 2.3 ± 1.6 \0.0001
Mean annualized relapse
rate
0.42 ± 0.84 0.34 ± 0.69 0.3083
Mean relapses 3 months
prior to treatment
0.56 ± 0.8 0.25 ± 0.6 \0.0001
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similar extent. Both parameters remained stable over
12 months observation time. The differences in baseline
clinical and demographic parameters between treatment
groups in this real-life dataset reflect the change in attitude
of neurologists and MS patients to optimize therapy at an
earlier stage with a lower disability and only single relap-
ses, if a safe and efficient therapeutic option is available.
Anyhow, these differences did not influence comparability
of the two strata as shown by regression analysis and
propensity scores.
These data show that FTY and N positively influence the
course of RRMS regarding degree of stabilization of EDSS
and reduction of relapses at a similar rate. Both drugs
achieve freedom of clinical disease activity in about two-
thirds of patients whose disease activity had not been
sufficiently controlled under first-line medication. These
Fig. 1 Mean EDSS score and
relapse rate in three months
intervals of therapy
Fig. 2 Number and percentages
of patients in EDSS strata and
free of clinical disease activity
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Fig. 3 Kaplan–Meyer survival
curves of patients free of
relapse, free of progression,
with freedom of clinical disease
activity over one year of
therapy with N or FTY
Table 2 Spearman correlation
coefficients
* p \ 0.05
Parameter Age Sex EDSS baseline Relapse rate baseline Therapy FTY vs. N
12 months r value r value r value r value r value
EDSS progression 0.038 0.046 -0.017 0.017 0.065
Relapse probability 0.149* -0.010 -0.136* -0.179* 0.046
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effects seem to be independent of baseline EDSS and
relapse rate. Longer observation periods with higher patient
numbers will show whether this trend toward improvement
of EDSS over 12 months in both treatment groups is real
and which patient strata will benefit most. These data
underline the importance of an early change in therapy of
RRMS if medication with interferons or glatirameracetate
does not achieve sufficient control of disease activity.
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